Effects of intravenous infusion of prostacyclin (PGI2) in man. 1980

J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada

Prostacyclin infused intravenously in human volunteers induces ex vivo inhibition of platelet aggregation, tachycardia and hypotension. The inhibition of platelet aggregation is obtained with slightly lower doses than those which exhibit cardiovascular effects. The cardiovascular effects disappeared within a few minutes after discontinuing the infusion of prostacyclin but the platelet effects were longer lasting. Prostacyclin did not have any effect on platelet count, platelet factor 3, accelerated partial thromboplastin time, prothrombin time, euglobulin clot lysis time, fibrinogen degradation products, blood glucose concentration or urine sodium potassium ratio.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
January 1982, The British journal of dermatology,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
August 1982, British journal of clinical pharmacology,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
August 1978, Thrombosis research,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
November 1984, European heart journal,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
April 1979, Prostaglandins,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
December 1983, British journal of clinical pharmacology,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
January 1983, Intensive care medicine,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
May 1982, Journal of applied physiology: respiratory, environmental and exercise physiology,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
July 1985, European heart journal,
J O'Grady, and S Warrington, and M J Moti, and S Bunting, and R Flower, and A S Fowle, and E A Higgs, and S Moncada
July 1991, Prostaglandins,
Copied contents to your clipboard!